Treace Medical Concepts forecasts revenue growth driven by new foot and ankle product launches and improved profitability metrics.
Treace Medical Concepts (TMCI) outlined Q2 2026 revenue guidance of $204M to $212M, reflecting sequential growth and expanded market reach. The company cited stronger adjusted EBITDA and reduced cash usage compared to the prior year as key drivers.
Management highlighted continued year-over-year case volume growth and profitability progress during its earnings call. The revenue projection aligns with broader product launches targeting the foot and ankle segment.
No immediate market reaction was disclosed in the source material.